EU/3/20/2337: Orphan designation for the treatment of limb-girdle muscular dystrophy
Table of contents
On 19 October 2020, orphan designation EU/3/20/2337 was granted by the European Commission to Premier Research Group S.L., Spain, for ribitol (also known as BBP-418) for the treatment of limb-girdle muscular dystrophy.
Treatment of limb-girdle muscular dystrophy
|Orphan designation status||
|EU designation number||
|Date of designation||
Bridge Bio Europe B.V.
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|February 2023||The sponsorship was transferred from Premier Research Group S.L., Spain to Bridge Bio Europe B.V., Netherlands.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: